Service de Radiologie, Nantes Université, CHU Nantes, 1 place Alexis Ricordeau, 44000, Nantes, France.
Service de Médecine Interne, Nantes Université, CHU Nantes, 1 place Alexis Ricordeau, 44000, Nantes, France.
Cardiovasc Intervent Radiol. 2022 Dec;45(12):1784-1792. doi: 10.1007/s00270-022-03247-3. Epub 2022 Aug 31.
To report the clinical effectiveness and the safety of cryoablation in first or second-line therapy in symptomatic soft tissues vascular malformation, a mini-invasive therapeutic alternative to sclerotherapy or surgery.
This retrospective and monocentric study included patients with symptomatic low-flow vascular malformation. The interventions were carried out under computed tomography (CT) scan, Cone-beam CT (CBCT) and/or USA guidance. Clinical response was evaluated by collecting the Numerical Rating Scale (NRS) for symptoms before and after the ablation. Safety was assessed based on criteria proposed by the Cardiovascular and Interventional Radiological Society of Europe. Imaging response was evaluated with post-ablation Magnetic Resonance Imaging.
Twenty-one patients were included. Cryoablation was the first operative treatment for 12 patients (12/21, 57%). The remaining patients had already undergone surgery (2/21, 9%) or one or more sclerotherapy procedures (7/21, 33%).Symptoms assessed by Numerical Rating Scale dropped from a median of 7 [IQR 6-8] before the procedure to a median of 1 [IQR 0-2] after cryoablation (p < 0.001). Half of the patients declared a full effectiveness of cryoablation on their symptoms (11/21). No major complications and four minor adverse events (two skin lesions, two patients with neuropathic pain) were reported (19%). Lesional volume significantly decreased after cryoablation (median from 3.7 cm [1-10.4] to 0.25 cm [0-2.0], p < 0.001).
Cryoablation seems to be a safe and effective first- or second-line therapy for soft tissue vascular malformations.
报告在有症状的软组织血管畸形的一线或二线治疗中,经皮冷冻消融的临床疗效和安全性,这是一种替代硬化治疗或手术的微创治疗选择。
这是一项回顾性单中心研究,纳入了有症状的低流速血管畸形患者。在计算机断层扫描(CT)、锥束 CT(CBCT)和/或超声引导下进行干预。通过收集消融前后症状的数字评分量表(NRS)来评估临床疗效。安全性根据欧洲心血管和介入放射学会提出的标准进行评估。消融后的磁共振成像(MRI)用于评估影像学反应。
共纳入 21 例患者。冷冻消融是 12 例患者(12/21,57%)的一线治疗。其余患者已经接受过手术(2/21,9%)或一次或多次硬化治疗(7/21,33%)。NRS 评估的症状在治疗前中位数为 7 [IQR 6-8],治疗后中位数为 1 [IQR 0-2](p<0.001)。一半的患者表示冷冻消融对其症状有完全疗效(11/21)。未报告重大并发症,仅发生了 4 例轻微不良事件(2 例皮肤损伤,2 例患者出现神经性疼痛)(19%)。冷冻消融后病变体积显著缩小(中位数从 3.7 cm [1-10.4]降至 0.25 cm [0-2.0],p<0.001)。
冷冻消融似乎是软组织血管畸形的一种安全有效的一线或二线治疗选择。